SelectMDx® (MDxHealth, Irvine, California, USA) is a clinically validated, commercially available biomarker-based risk score developed to assess the probability of detecting high-grade PCa on prostate biopsy using urinary HOXC6 and DLX1 mRNA expression levels combined with traditional clinical risk factors, such as serum PSA, PSA density, DRE status, age, and family history of PCa. Here, DLX1 is linked to posterior cortical atrophy.